On July 17, Johnson & Johnson (NYSE: JNJ) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare conglomerate's needle forward for years to come.

Johnson & Johnson is made of many pieces that aren't moving in the same direction. Remicade, Imbruvica, and Zytiga are three blockbuster drugs in the company's pharmaceutical lineup that are losing ground to new competition.

Is Johnson & Johnson still a good dividend stock to buy? Let's weigh its strengths and opportunities against some challenges it faces to find out.

Continue reading

Source Fool.com